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BACKGROUND: MicroRNAs (miRNAs) are small noncoding RNAs that have important roles in numerous cellular processes. Recent
studies have shown aberrant expression of miRNAs in prostate cancer tissues and cell lines. On the basis of miRNA microarray data,
we found that miR-145 is significantly downregulated in prostate cancer.
METHODS AND RESULTS: We investigated the expression and functional significance of miR-145 in prostate cancer. The expression of
miR-145 was low in all the prostate cell lines tested (PC3, LNCaP and DU145) compared with the normal cell line, PWR-1E, and in
cancerous regions of human prostate tissue when compared with the matched adjacent normal. Overexpression of miR-145 in
PC3-transfected cells resulted in increased apoptosis and an increase in cells in the G2/M phase, as detected by flow cytometry.
Investigation of the mechanisms of inactivation of miR-145 through epigenetic pathways revealed significant DNA methylation of the
miR-145 promoter region in prostate cancer cell lines. Microarray analyses of miR-145-overexpressing PC3 cells showed upregulation
of the pro-apoptotic gene TNFSF10, which was confirmed by real-time PCR and western analysis.
CONCLUSION: One of the genes significantly upregulated by miR-145 overexpression is the proapoptotic gene TNFSF10. Therefore,
modulation of miR-145 may be an important therapeutic approach for the management of prostate cancer.
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Micro RNAs (miRNAs) are small noncoding RNAs that regulate
the expression of protein-coding genes (He and Hannon, 2004; Lim
et al, 2005; Volinia et al, 2006). MicroRNAs have important roles in
numerous cellular processes, including development, proliferation
and apoptosis (Carrington and Ambros, 2003). Characteristic
miRNA signatures for several epithelial cancers, including breast,
lung, pancreatic and gastric cancers, have been reported (Iorio
et al, 2005; Yanaihara et al, 2006; Bloomston et al, 2007; Petrocca
et al, 2008). Micro RNAs control gene expression by binding to
complementary sites in the 30 untranslated regions (30 UTRs) of
target mRNAs, triggering either translational inhibition or mRNA
degradation (Baek et al, 2008). However, miRNAs can also
function to positively regulate gene expression by binding to
complementary or partial complementary sequences in the
promoter regions of genes (Place et al, 2008). Recent studies have
shown the aberrant expression of miRNAs in prostate cancer
tissues and cell lines (Galardi et al, 2007; Porkka et al, 2007; Ozen
et al, 2008). One of the miRNAs reported to be consistently
downregulated in prostate tumours is miR-145, and it has been
shown to act as a tumour suppressor in breast and colon cancers
(Schepeler et al, 2008; Spizzo et al, 2009).
In this study we analysed the functional significance of miR-145
in prostate cancer. We examined the expression level of miR-145
in 27 matched human prostate cancer laser microdissected tissue
samples, and found a significant difference between adjacent
normal and cancerous regions. We also investigated whether the
mechanism of inactivation of miR-145 in prostate cancer cell lines
is through methylation of its promoter. After combination
treatments with low doses of genistein (G), 5-aza-20-deoxycytidine
(5-aza) and trichostatin A (TSA), there was an increase in the
expression of miR-145, suggesting that silencing of miR-145 is
through DNA methylation. To identify potential miR-145 targets,
we performed microarray analyses in miR-145-overexpressing
prostate cancer cells and found upregulation of the pro-apoptotic
gene TNFSF10. We also observed that overexpression of miR-145
in PC3 cells led to cell cycle arrest and increased apoptosis. This is
the first report on the mechanisms of inactivation of miR-145
through DNA methylation in prostate cancer.
MATERIALS AND METHODS
Cell lines and cell culture
Human prostate carcinoma cell lines, PC3, LNCaP and Du145, and
the normal epithelial prostate cell line, PWR-1E, were obtained
from the American Type Culture Collection (ATCC, Manassas, VA,
USA). The prostate cancer cell lines were cultured as monolayers
in RPMI-1640 (UCSF Cell Culture Facility, San Francisco, CA,
USA) supplemented with 10% foetal bovine serum (Hyclone,
Logan, UT, USA), 50mgml
–1 penicillin and 50mgml
–1 strepto-
mycin (Invitrogen, Carlsbad, CA, USA), and maintained in an
incubator with a humidified atmosphere of 95% air and 5% CO2 at
371C. The PWR-1E cells were cultured in keratinocyte growth
medium supplemented with 5ngml
–1 human recombinant
epidermal growth factor and 0.05mgml
–1bovine pituitary extract
(Life Technologies/Invitrogen, Carlsbad, CA, USA) and maintained
in an incubator under the conditions described above.
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concentrations of genistein (25mM), 5-aza (5mM) and TSA
(100ngml
–1). Genistein (Sigma-Aldrich Corp., St Louis, MO,
USA) was dissolved in DMSO, and cells treated only with vehicle
(DMSO) served as control. Fresh genistein and 5-aza (Sigma) were
administered everyday along with a change of medium, and the
cells were grown for 96h. Trichostatin A (Upstate Biotech, Lake
Placid, NY, USA) was administered for the last 24h of treatment.
Quantitative real-time PCR
First-strand cDNA was prepared from total RNA (1mg) using the
reverse transcription system (Promega, Madison, WI, USA). Total
RNA was extracted using the RNeasy mini kit from Qiagen
(Valencia, CA, USA). In the real-time polymerase chain reaction
(PCR) step, complementary DNA was amplified with Inventoried
Gene Assay Products containing two gene-specific primers and
one TaqMan MGB probe (6-FAM dye-labeled) using the TaqMan
Universal Fast PCR Master Mix in a 7500 Fast Real-Time PCR
System (Applied Biosystems, Foster City, CA, USA). Thermal
cycling conditions included 951C for 20s, 40 cycles of 951C for 3s
and 601C for 30s according to the TaqMan Fast Universal PCR
protocol. GAPDH was used as an endogenous control. For miRNA
real-time experiments the cDNA strand was synthesised using
Applied Biosystems Taqman MicroRNA Reverse Transcription kit,
using a total of 200ng of total extracted miRNA. RNU48 was used
as an endogenous control. In real-time experiments, in which
miRNAs were isolated from formalin-fixed paraffin-embedded
(FFPE) prostate samples, let7-f was used as an endogenous control.
Total miRNA was extracted from the FFPE samples using the
miRNA FFPE kit from Qiagen.
Laser capture microdissection (LCM) and RNA extraction
from FFPE human prostate tumour samples
Adjacent normal and cancerous prostate tissues were obtained
from 27 representative FFPE tissue blocks of radical prostatectomy
specimens from the Pathology Department of the Veterans Affairs
Medical Center of San Francisco. For the identification of prostatic
adenocarcinoma as well as normal and hyperplastic glandular
epithelium and stroma, the slides were reviewed by a certified
pathologist. Microdissection of cancerous and adjacent normal
regions was performed using the Arcturus Autopix system from
Molecular Devices (Sunnyvale, CA, USA). In short, 8mm sections
were placed on glass slides, deparaffinised, stained with haema-
toxylin, dehydrated and placed in the Arcturus instrument for
microdissection. Tissue samples of the different cancerous and
adjacent normal regions were captured with infrared laser pulses
onto CapSure Macro LCM caps and RNA was extracted following
the instructions in the miRNA FFPE kit from Qiagen. The levels of
miR-145 were assessed by the Taqman miR assay as described
above. The relative miR-145 expression levels in cancerous regions
were normalised to their adjacent normals (value 1).
Sodium bisulphite modification and sequencing
Bisulphite modification of DNA was performed using the Epi-Tect
Bisulphite kit (Qiagen) following the manufacturer’s directions.
The basic principle of bisulphite modification of DNA is that in the
bisulphite reaction, all unmethylated cytosines are deaminated and
sulphonated, converting them to thymines, whereas methylated
cytonies (5-methylcytosines) remain unaltered. Thus, the
sequence of the treated DNA will differ depending on whether
the DNA is originally methylated or unmethylated. Primers for
bisulphite genomic sequencing PCR were designed using the
online program MethPrimer (Li and Dahiya, 2002). All reactions
for tissue samples were subjected to two rounds of amplifications
using a nested primer approach. Bisulphite-modified DNA (1ml)
was amplified using a primer pair in a total volume of 20ml.
Aliquots (2ml) of the first PCR reactions were subjected to second-
round amplifications using a pair of nested primers in a total
volume of 30ml. The amplification products were confirmed by
electrophoresis on a 2% agarose gel and sequenced directly by an
outside vendor (McLab, South San Francisco, CA, USA).
Cell transfection
PC3 cells were transiently transfected with either precursors of
miRNA-145 or negative control 1 (both from Ambion, Austin, TX,
USA), using Lipofectamine reagent (Invitrogen), according to the
manufacturer’s recommendations. In brief, cells were seeded in
100mm dishes (Nunc, Roskilde, Denmark) 24h before transfection
and were transiently transfected at a confluency of 40–50%. Mock
transfection, which only had the transfection reagent, was also
used as a control. The transfection mixture was dissolved in
Opti-MEM serum-free media (Invitrogen) and at the time of
transfection cells were seeded in RPMI-1640 media (UCSF Cell
culture facility), with 10% FBS (Atlanta Biologicals, Lawrenceville,
GA, USA) and no antibiotics. On the subsequent day the media was
changed and RPMI media containing both FBS and 1% antibiotic
(penicillin–streptomycin, 100 , UCSF Cell Culture Facility) was
added to the cells. Cells were pelleted after 72h of transfection for
flow cytometry, RNA and protein extraction.
Cell proliferation assay
For cell proliferation assay, PC3 cells were seeded in 96-well
microplates at a density of 5 10
3 cells per well 24h before
transfection. After transfection, cell viability was determined at 24,
48 and 72h using the CellTiter 96 Aqueous One Solution Cell
Proliferation Assay kit (Promega) according to the manufacturer’s
protocol. Absorbance at 490nm was measured with a kinetic
microplate reader (Spectra MAX 190; Molecular Devices) and was
used as a measure of cell number. Experiments were performed in
quadruplicate and repeated three times.
Cell cycle analysis
Cell cycle analysis was performed 72h after transfection. The cells
were harvested, washed with cold PBS, UCSF Cell Culture Facility,
and resuspended in the nuclear stain 40,6-diamidino-2-phenylin-
dole (Beckman Coulter, Brea, CA, USA). Stained cells were
immediately analysed with a flow cytometer (Cell Lab Quanta
SC; Beckman Coulter).
Apoptosis assay
For apoptosis, transfected cells at 72h after transfection were dual
stained with the viability dye 7-amino-actinomycin D and Annexin
V-FITC using Annexin V-FITC/7-amino-actinomycin D kit
(Beckman Coulter) according to the manufacturer’s protocol.
Stained cells were immediately analysed by flow cytometry (Cell
Lab Quanta SC; Beckman Coulter).
Western analysis
Whole-cell extracts were prepared in radioimmunoprecipitation
assay buffer (RIPA; Thermo Scientific, Rockford, IL, USA;
50mmoll
–1Tris (pH 8.0), 150mmoll
–1 NaCl, 0.5% deoxycholate,
0.1% SDS and 1.0% NP-40) containing 1  protease inhibitor
cocktail (Roche, Basel, Switzerland). Protein estimations were
performed using a BCA Protein assay kit (Pierce/Thermo
Scientific, Rockford, IL, USA) according to the manufacturer’s
instructions. Total protein (40mg) was electrophoresed in 15%
SDS–PAGE gels, and western blotting was carried out using
standard protocols and detected by chemiluminescence.
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no. 3136) and GAPDH (cat. no. 2118), were purchased from Cell
Signaling (Danvers, MA, USA).
Statistical analysis
Statistical analysis was performed using StatView version 5.0 for
Windows as needed. Student’s t-test was used to compare the
different groups. The P-values of o0.05 were regarded as
statistically significant.
RESULTS
Expression of miR-145 in prostate cell lines and
human tissues
We first checked the expression levels of miR-145 in prostate cell
lines and human tissue samples. The cell lines used were PC3,
LNCaP, Du145 and PWR-1E, in which PC3, LNCaP and Du145
were prostate cancer cell lines, whereas PWR-1E was a normal
prostatic epithelial cell line. The expression of miR-145 was found
to be low in all the prostate cancer cell lines tested (untreated PC3,
LNCaP and Du145) when compared with the normal PWR-1E cells
(Figure 1A). Treatment with 5-aza resulted in a significant
increase in the expression of miR-145 in all cell lines, which
suggests epigenetic silencing of this miRNA in the prostate
cancer cell lines (Figure 1B). Subsequently, we examined 27
matched prostate cancer laser microdissected human tissue
samples. The level of miR-145 expression in adjacent normal
regions was found to be significantly higher when compared with
matched cancerous regions in 80% of the samples tested
(Figure 1C).
miR-145 promoter CpG island methylation and increased
expression with 5-aza treatment
To elucidate the low expression of miR-145 in prostate cells and
tumours, we analysed the methylation status of the 50 upstream
region of the miR-145 gene. In prostate cancer cell lines, PC3,
LNCaP and Du145, there are 10 CpG sites in the 50 upstream region
of miR-145. In the first 100 bases proximal to the start site, all the
CpG sites were found to be completely methylated in these cell
lines (Figure 2). In PC3 cells the CpG sites in the second 100 bases
were also completely methylated, whereas in the other two the
percentage of methylation of these CpG sites decreased to 40% in
LNCaP cells. We also checked the methylation levels in prostate
carcinoma tissue samples. Out of the 10 samples checked, all had
high levels of methylation (470–80%, data not shown). To see
whether the low level of miR-145 in prostate cancer cell lines is
because of methylation, we treated PC3, LNCaP and Du145 cells
with the demethylating agent 5-aza deoxycytidine. After extracting
the total miRNA from these treated cell lines, real-time PCR
showed an increase in expression of miR-145 levels of
approximately 148, 18- and 64-fold in Du145, LNCaP and PC3
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Figure 1 miR-145 expression is silenced in prostate cancer cell lines and tumour samples. (A) Level of miR-145 in untreated PC3, LNCaP, Du145 and
PWR-1E cell lines. The expression of miR-145 was found to be low in all the prostate cancer cell lines tested (untreated PC3, LNCaP and Du145) when
compared with the normal PWR-1E cells. (B) 5-aza treatment of prostate cancer cell lines resulted in a significant increase in the expression of miR-145.
(C) Relative miR-145 levels in cancerous regions of prostate tissue, as normalised to adjacent normal (value 1). The level of miR-145 expression in adjacent
normal prostate tissue regions was found to be significantly higher when compared with the matched cancerous regions in 80% of the samples tested.
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This suggests that methylation of the 50 upstream regions of the
miR-145 gene is one of the factors responsible for its low
expression in prostate cancer cells.
Effect of genistein, 5-aza and TSA on miR-145 expression
Owing to the toxicity of the individual treatment agents (genistein,
5-aza and TSA) at high concentrations, all the compounds were
used at a comparatively low dose. PC3 cells were treated with
genistein (25mM), 5-aza (5mM) and TSA (100ng ml
–1), individually
and in combination for 96h. Genistein and 5-aza were adminis-
tered for the total time period, whereas TSA was administered for
the last 24h. Subsequently, total miRNA was extracted and the
level of miR-145 was analysed by real-time PCR. The expression
level of miR-145 increased significantly in 5-aza-treated cells
(Figure 3) and the highest levels were observed in combination
with genistein, 5-aza and TSA (Figure 3).
Effect of overexpression of miR-145 in PC3 cells
To see the effect of overexpression of miR-145 on prostate cell
lines, pre-miR-145, a precursor of miR-145, was transfected into
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Figure 3 Effect of genistein, 5-aza and TSA on miR-145 expression in PC3 cells. Genistein in combination with 5-aza and TSA significantly increased
miR-145 levels.
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Figure 2 Methylation status of the 50 upstream region of the miR-145
transcription start site in prostate cancer cell lines. The x axis denotes the
number of bases. The þve and  ve values attached to the bases
represent downstream (þve) and upstream ( ve) of the putative
transcriptional start site of the precursor of miR-145. The y axis indicates
the percentage of methylation in the CpG sites.
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Figure 4 Overexpression of miR-145 in PC3 cells. (A) Increase in the
level of miR-145 after transfection in PC3 cells. (B) Decrease in cell viability
in a time-dependent manner in miR-145-transfected cells compared with
the negative control and mock samples.
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transfection showed expression of miR-145 at 41000-fold over
control (Figure 4A). We monitored cellular proliferation after miR-
145 upregulation in PC3 cells and found that cell viability
significantly decreased in a time-dependent manner in miR-145-
transfected cells compared with the negative control and mock
samples (Figure 4B). The data were normalised to the mock
sample. This suggests that the attenuation of miR-145 expression
has an antiproliferative effect on PC3 cells.
The effects of miR-145 overexpression on the cell cycle and
apoptosis were analysed using flow cytometry. Cell cycle analyses
showed a decrease in the G0–G1 stage with a concomitant increase
in cells in G2–M phase in case of the cells transfected with a
precursor of miR-145 when compared with both mock and the
negative control (Figure 5A). The effect of miR-145 upregulation
on apoptosis showed a 5% increase in the total number of cells
undergoing apoptosis (apoptotic and early apoptotic) in miR-145-
transfected cells when compared with both negative control and
mock (Figure 5B). We also checked the effect of upregulation of
miR-145 in prostate cancer cell lines, LNCaP and Du145. No
significant effect was observed in the case of LNCaP cells in both
cell cycle and apoptosis. Although, in the case of Du145 cell cycle
analysis showed an increase of B9% in the cells in G0–G1 stage, in
miR-145-transfected cells, when compared with mock, it showed a
concomitant decrease of B7% in cells in G2–M phase (Figure 5C).
Apoptosis showed a significant increase (B11%) in the total
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Figure 5 Flow cytometry analysis of miR-145-transfected PC3 cells. (A) Cell cycle analyses showed a decrease in the G0–G1 stage with a concomitant
increase in cells in the G2–M phase in those cells transfected with a precursor of miR-145 when compared with both mock and negative control.
(B) miR-145 upregulation increased apoptosis (5%) in the total number of PC3 cells undergoing apoptosis (apoptotic and early apoptotic) in miR-145-
transfected PC3 cells when compared with both negative control and mock. (C) Cell cycle analysis of miR-145-transfected Du145 cells showed an increase
of B9% in the cells in G0–G1 stage when compared with mock, with a concomitant decrease of B7% of cells in the G2–M phase. (D) There was a
significant increase (B11%) in the total number of Du145 cells undergoing apoptosis (apoptotic and early apoptotic) in the miR-145-transfected Du145 cells
when compared with mock.
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apoptotic) in the miR-145-transfected cells when compared with
mock (Figure 5D).
mRNA microarray of miR-145-overexpressing PC3 cells
Micro RNAs are known to have numerous cellular targets.
Therefore, we analysed the changes occurring as a result of
miR-145 overexpression in PC3 cells using mRNA microarray
(data not shown). These results showed the upregulation of a
number of pro-apoptotic genes such as TNFSF10 and IL-24
(Pitti et al, 1996; Sauane et al, 2004), and cyclin binding ubiquitin
ligases such as HERC5 (Hochrainer et al, 2008). There was also
downregulation of antiapoptotic genes such as BIRC5 (Tamm et al,
1998), also known as survivin and of the prometastatic gene FSCN1
(Hashimoto et al, 2009).
TNFSF10 is increased after miR-145 transfection in PC3
The results of the microarray were validated by real-time PCR. The
mRNA expression level of TNFSF10, HERC5 and IL-24 was found
to be upregulated by approximately 132-, 16- and 3.5-fold,
respectively, by the transfection of miR-145 in PC3 cells (Figure
6A–C). TNFSF10, a member of the family of TRAIL (TNF-related
apoptosis-inducing ligands) molecules (Pitti et al, 1996) had the
maximum increase in mRNA levels by real-time PCR. Its
expression was further substantiated by checking the level of
protein expression of TNFSF10 by western blotting in the
transfected PC3 cells. Protein expression of TNFSF10 was found
to be substantially upregulated for the miR-145 sample when
compared with the negative control (Figure 6D). Moreover, we also
checked the protein expression of different genes that are involved
in regulating apoptosis and cell cycle. Among these were survivin,
Bcl-2, cdc7, cdk6 and PUMA. Out of these, only cdk6 showed a
significant decrease in its expression in the miR-145-transfected
sample when compared with the negative control (Figure 6D).
DISCUSSION
Prostate cancer accounts for approximately 29% of cancer
incidence and is second only to lung cancer in male cancer deaths
in the United States (Jemal et al, 2007). Treatments available for
this disease include hormone therapy, radical prostatectomy or
irradiation. Generally, a subset of prostate cancer patients is prone
to disease relapse and metastasis, which frequently develops even
after surgery and may cause death. Therefore, a number of
alternative ways for controlling prostate cancer have emerged,
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genesis by pharmacologic intervention with naturally occurring or
synthetic agents (Sporn and Suh, 2002; Tsao et al, 2004).
Tumourigenesis is a multistep process that results from the
accumulation and interplay of genetic and epigenetic changes.
Increased DNA methylation of CpG islands in the promoter region
of genes is well established as a common epigenetic mechanism for
the silencing of tumour suppressor genes (TSGs) in cancer cells
(Jones and Laird, 1999). Epigenetic silencing of a gene can be
reversed by drugs such as 5-aza-20-deoxycytidine (5Aza-C) that
forms a covalent complex with the active site of methyltransferase
resulting in generalised demethylation. Unfortunately, the applic-
ability of this commonly used drug is hampered by its high toxicity
and instability in physiological solutions (Bender et al, 1998).
Histone deacetylases (HDACs) are frequently overexpressed in a
broad range of cancer types, in which they alter cellular epigenetic
programming to promote cell proliferation and survival (Marks
et al, 2001). HDAC inhibitors are presently approved for treatment
of advanced primary cutaneous T-cell lymphoma (Mann et al,
2007), and have been shown to be effective in animal models of
prostate cancer (Wedel et al, 2008). In a previous study, it has
been shown that treatment of prostate cancer cells with the
HDAC inhibitor TSA induces cell cycle arrest but not apoptosis
(Roy et al, 2005).
Epidemiologic evidence suggests that intake of a soy-rich diet
may have a protective effect against prostate cancer (Hebert et al,
1998; Jacobsen et al, 1998). Genistein, one of the principal soy
isoflavones, shows a wide array of chemopreventive actions. The
anticancer effects of genistein have been ascribed to several
signalling pathways and mechanisms that lead to cell cycle arrest,
apoptosis, invasion, metastasis and angiogenesis, the attributes
that could potentially prevent tumour initiation and progression
(Magee and Rowland, 2004; Bektic et al, 2005). Genistein (40,5,7-
trihydroxyflavone) is a naturally occurring isoflavenoid that is
abundant in soy products and has been identified as an inhibitor of
protein tyrosine kinases and thus it has a key role in cell growth
and apoptosis (Hunter, 1987; Ullrich and Schlessinger, 1990).
It has been reported to have estrogenic properties and anti-
neoplastic activity in multiple tumour types (Zava and Duwe,
1997). It was also found to have epigenetic effects in the mouse
prostate (Day et al, 2002). The above findings prompted us to
examine its effect on the expression of miRNAs. Furthermore, the
role of 5-aza and TSA in the reversal of epigenetic silencing
of genes prompted us to use them in combination with genistein.
Micro RNAs have important roles in many biological processes,
including cell growth, apoptosis, haematopoietic lineage differ-
entiation and gene regulation. They are also involved in a wide
variety of human diseases such as cancer, vascular disease,
immune disease and infections. More than 50% of human miRNA
genes are thought to be located in cancer-associated regions or at
fragile sites of chromosomes, which are hot spots for gene deletion,
amplification and mutations. Many genomic profiling studies have
indicated a general downregulation of miRNAs in various
tumours, including pancreatic cancer, breast cancer, prostate
cancer, liver cancer, colon cancer and ovarian cancer, suggesting a
more negative regulation of cancer growth by miRNAs (Graman-
tieri et al, 2007; Hurteau et al, 2007; Lee et al, 2007; Shi et al, 2007;
Barbarotto et al, 2008; Felicetti et al, 2008; Mitomo et al, 2008;
Schetter et al, 2008; Yang et al, 2008).
The consistency with which miR-145 was found to be down-
regulated in both prostate cell lines and carcinoma samples
prompted us to examine the role it has in prostate cancer. It is
evident from our results that loss of miR-145 might be important
in the development and progression of prostate cancer, as it’s
overexpression resulted in an increase in the total number of cells
undergoing apoptosis. This led us to hypothesise that miR-145
might be affecting apoptosis. mRNA microarray of the over-
expressed miR-145 in PC3 cells confirmed our hypothesis when we
observed the upregulation of pro-apoptotic genes such as TNFSF10
and IL-24. Real-time PCR of TNFSF10 mRNA showed upregulation
of its expression (132-fold), which was confirmed by western
blotting. TNFSF10, also known as TRAIL or Apo-2 ligand (Pitti
et al, 1996), is a member of the TNF superfamily, and since its
discovery it has been used as an antitumour protein because of its
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Figure 6 Effect of miR-145 overexpression on apoptosis/cell cycle genes
in PC3 cells. Increased expression of (A) TNFSF10, (B) HERC5 and (C)
IL24 in miR-145-transfected PC3 cells when compared with mock and the
negative control. (D) Western analysis of upregulated and downregulated
genes in miR-145-transfected PC3 cells. Upregulation of TNFSF10 protein
expression occurred concomitantly with downregulation of cdk6 in PC3
cells transfected with miR-145 precursor.
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sability to induce apoptosis in a variety of human cancer cell lines
while leaving normal cells unaffected (Walczak et al, 1999).
Moreover, studies performed on TRAIL knockout mice show that
TNFSF10 has an important role in normal tumour immuno-
surveillance as TNFSF10 knockout mice support tumour growth at
a higher rate when compared with normal mice and are more
susceptible to tumour metastasis (Cretney et al, 2002). Cells
undergoing TRAIL-induced death show many of the hallmarks of
apoptosis, including DNA fragmentation, expression of pro-
phagocytic signals on the cell membrane and cleavage of multiple
intracellular proteins by caspases (Griffith et al, 1998).
In summary, our results suggest methylation of the promoter
region of miR-145 in prostate cancer cell lines and prostate cancer
tissue samples as a major reason for its low expression. This is the
first report on the mechanism of inactivation of miR-145 through
DNA methylation as well as the functional significance of miR-145
in prostate cancer. As one of the genes significantly upregulated by
miR-145 overexpression is the pro-apoptotic TNFSF10 gene,
modulation of miR-145 may be an important therapeutic approach
for the management of prostate cancer.
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